Karyopharm Therapeutics (KPTI) Earnings Date, Estimates & Call Transcripts

$0.86

+0.01 (+1.17%)

(As of 10/11/2024 ET)

Upcoming Earnings Date: Nov. 7Estimated
Actual EPS (Aug. 6): -$0.20 Beat By $0.09
Consensus EPS (Aug. 6): -$0.29

KPTI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KPTI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ad Crypto 101 Media

[SHOCKING] Crypto Document Leak…

A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move is being made in preparation to onboard all of Sony products (including Sony's Playstation, which captured a record 62% share of the global gaming console market in 2024). Enthusiasts and experts are buzzing with anticipation qnd one little-known crypto coin is poised for RAPID growth as we see this all unfold.

Click here to review my research and unique strategy to score potential profits from this under-the-

Karyopharm Therapeutics Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate	Company Guidance
Q1 2024	3	($0.37)	($0.09)	($0.27)
Q2 2024	2	($0.32)	($0.08)	($0.20)
Q3 2024	3	($0.34)	($0.06)	($0.23)
Q4 2024	3	($0.31)	($0.06)	($0.22)
FY 2024	11	($1.34)	($0.29)		($0.92)

KPTI Earnings Date and Information

Karyopharm Therapeutics last posted its earnings results on August 6th, 2024. The reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.09. The firm had revenue of $42.79 million for the quarter, compared to analysts' expectations of $36.07 million. Karyopharm Therapeutics has generated ($1.18) earnings per share over the last year (($1.18) diluted earnings per share). Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.66) per share. Karyopharm Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off prior year's report dates.

Karyopharm Therapeutics Earnings History by Quarter

Time Frame

Start Date

End Date

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
11/7/2024 (Estimated)	-	-	-	-	-	-	-
8/6/2024	Q2 2024	($0.29)	($0.20)	+$0.09	($0.20)	$36.07 million	$42.79 million
5/8/2024	Q1 2024	($0.33)	($0.32)	+$0.01	($0.32)	$35.02 million	$33.13 million
2/29/2024	Q4 2023	($0.29)	($0.36)	($0.07)	($0.36)	$33.50 million	$33.75 million
11/2/2023	Q3 2023	($0.28)	($0.30)	($0.02)	($0.30)	$37.34 million	$36.01 million
8/2/2023	Q2 2023	($0.34)	($0.29)	+$0.05	($0.29)	$36.23 million	$37.58 million
5/4/2023	Q1 2023	($0.34)	($0.30)	+$0.04	($0.30)	$37.87 million	$38.70 million
Get the Latest News and Ratings for KPTI and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
2/15/2023	Q4 2022	($0.34)	($0.43)	($0.09)	($0.43)	$33.88 million	$33.58 million
11/3/2022	Q3 2022	($0.56)	($0.45)	+$0.11	($0.45)	$34.82 million	$36.15 million
8/4/2022	Q2 2022	($0.63)	($0.62)	+$0.01	($0.62)	$36.38 million	$39.68 million
5/5/2022	Q1 2022	($0.63)	($0.53)	+$0.10	($0.53)	$34.78 million	$47.67 million
2/8/2022	Q4 2021	($0.40)	$0.46	+$0.86	$0.46	$55.98 million	$126.27 million
11/3/2021	Q3 2021	($0.68)	($0.69)	($0.01)	($0.69)	$25.84 million	$37.69 million
8/5/2021	Q2 2021	($0.72)	($0.71)	+$0.01	($0.71)	$26.86 million	$22.60 million
5/2/2021	Q1 2021	($0.71)	($0.77)	($0.06)	($0.77)	$26.50 million	$23.26 million
2/11/2021	Q4 2020	($0.58)	($0.59)	($0.01)	($0.59)	$35.39 million	$35.10 million
11/2/2020	Q3 2020	($0.73)	($0.73)	-	($0.73)	$21.35 million	$21.33 million
8/4/2020	Q2 2020	($0.57)	($0.63)	($0.06)	($0.63)	$28.03 million	$33.51 million
5/5/2020	Q1 2020	($0.69)	($0.78)	($0.09)	($0.78)	$21.59 million	$18.14 million
2/13/2020	Q4 2019	($0.66)	($0.76)	($0.10)	($0.76)	$16.48 million	$18.10 million
11/4/2019	Q3 2019	($0.84)	($0.6662)	+$0.1738	($0.67)	$1.61 million	$13.15 million

Karyopharm Therapeutics Earnings - Frequently Asked Questions

When is Karyopharm Therapeutics's earnings date?: Karyopharm Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates. Learn more on KPTI's earnings history.
What guidance has Karyopharm Therapeutics issued on next quarter's earnings?: Karyopharm Therapeutics updated its FY 2024 earnings guidance on Tuesday, August, 6th. The company issued revenue guidance of $145.0 million-$160.0 million, compared to the consensus revenue estimate of $145.4 million.
Did Karyopharm Therapeutics beat their earnings estimates last quarter?: In the previous quarter, Karyopharm Therapeutics (NASDAQ:KPTI) reported ($0.20) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.29) by $0.09. Learn more on analysts' earnings estimate vs. KPTI's actual earnings.
How much revenue does Karyopharm Therapeutics generate each year?: Karyopharm Therapeutics (NASDAQ:KPTI) has a recorded annual revenue of $146.03 million.
How much profit does Karyopharm Therapeutics generate each year?: Karyopharm Therapeutics (NASDAQ:KPTI) has a recorded net income of -$143.10 million. KPTI has generated -$1.18 earnings per share over the last four quarters.
What is Karyopharm Therapeutics's EPS forecast for next year?: Karyopharm Therapeutics's earnings are expected to grow from ($0.93) per share to ($0.66) per share in the next year.